AKTS (Aktis Oncology) Notes Receivable: $0.00 Mil (As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.76
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Notes Receivable?

Aktis Oncology AKTS +2.82% 9 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

Aktis Oncology's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Aktis Oncology Notes Receivable Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Notes Receivable Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
AKTS
9GF Score
Aktis Oncology Inc AKTS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Aktis Oncology (AKTS) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Notes Receivable too high?
Aktis Oncology's current Notes Receivable is $0.00 Mil. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Notes Receivable compare to ZBIO and MLTX?
Aktis Oncology's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.76
Price